Acorda Therapeutics (ACOR) Misses Q1 EPS by 33c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acorda Provides Financial and Pipeline Update for First Quarter 2018
May 2, 2018 6:00 AM EDTFDA accepted INBRIJA (levodopa inhalation powder) NDA; PDUFA date October 5, 2018 Marketing Authorization Application (MAA) for INBRIJA submitted to the European Medicines Agency (EMA) on March 26, 2018 AMPYRA® (dalfampridine) 1Q 2018 net sales of $103 million; reiterates 2018 guidance of $330-$350 million AMPYRA oral argument at U.S. Court of Appeals scheduled for June 7, 2018
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:... More
